Eporatio

Country: European Union

Language: Slovenian

Source: EMA (European Medicines Agency)

Buy It Now

Active ingredient:

epoetin theta

Available from:

Ratiopharm GmbH

ATC code:

B03XA01

INN (International Name):

epoetin theta

Therapeutic group:

Drugi antianemic priprave

Therapeutic area:

Kidney Failure, Chronic; Anemia; Cancer

Therapeutic indications:

Zdravljenje simptomatske anemije, povezane s kronično ledvično odpovedjo pri odraslih bolnikih. Zdravljenje simptomatsko anemija pri odraslih bolnikov z rakom z non-mieloično malignancies, ki prejemajo kemoterapijo.

Product summary:

Revision: 13

Authorization status:

Pooblaščeni

Authorization date:

2009-10-29

Patient Information leaflet

                                23
8.
DATUM IZTEKA ROKA UPORABNOSTI ZDRAVILA
EXP
Sedem dni se lahko shranjuje pri sobni temperaturi (ne nad 25
°
C), vendar ne po izteku roka
uporabnosti.
Konec sedemdnevnega obdobja na sobni temperaturi: __/__/____
9.
POSEBNA NAVODILA ZA SHRANJEVANJE
Shranjujte v hladilniku.
Ne zamrzujte.
Napolnjeno injekcijsko brizgo shranjujte v zunanji škatli za
zagotovitev zaščite pred svetlobo.
10.
POSEBNI VARNOSTNI UKREPI ZA ODSTRANJEVANJE NEUPORABLJENIH
ZDRAVIL ALI IZ NJIH NASTALIH ODPADNIH SNOVI, KADAR SO POTREBNI
11.
IME IN NASLOV IMETNIKA DOVOLJENJA ZA PROMET Z ZDRAVILOM
ratiopharm GmbH
Graf-Arco-Straße 3
89079 Ulm
Nemčija
12.
ŠTEVILKA(E) DOVOLJENJA (DOVOLJENJ) ZA PROMET
EU/1/09/573/001 6 napolnjenih injekcijskih brizg
EU/1/09/573/002 6 napolnjenih injekcijskih brizg z varnostnim
pripomočkom
EU/1/09/573/029 6 napolnjenih injekcijskih brizg z varnostno iglo
13.
ŠTEVILKA SERIJE
Lot
14.
NAČIN IZDAJANJA ZDRAVILA
Predpisovanje in izdaja zdravila je le na recept.
15.
NAVODILA ZA UPORABO
16.
PODATKI V BRAILLOVI PISAVI
Eporatio 1000 i.e./0,5 ml
24
17.
EDINSTVENA OZNAKA – DVODIMENZIONALNA ČRTNA KODA_ _
Vsebuje dvodimenzionalno črtno kodo z edinstveno oznako.
18.
EDINSTVENA OZNAKA – V BERLJIVI OBLIKI_ _
PC
SN
NN
25
PODATKI NA ZUNANJI OVOJNINI
ŠKATLA
1.
IME ZDRAVILA
Eporatio 2000 i.e./0,5 ml raztopina za injiciranje v napolnjeni
injekcijski brizgi
epoetin theta
2.
NAVEDBA ENE ALI VEČ ZDRAVILNIH UČINKOVIN
Ena napolnjena injekcijska brizga vsebuje 2000 mednarodnih enot (i.e.)
(16,7 mikrograma) epoetina
theta v 0,5 ml raztopine za injiciranje, kar ustreza 4000 i.e. (33,3
mikrograma) epoetina theta na ml.
3.
SEZNAM POMOŽNIH SNOVI
Pomožne snovi: natrijev dihidrogenfosfatdihidrat, natrijev klorid,
polisorbat 20, trometamol,
klorovodikova kislina (6 M) (za uravnavanje pH), voda za injekcije.
4.
FARMACEVTSKA OBLIKA IN VSEBINA
raztopina za injiciranje
6 napolnjenih injekcijskih brizg, ki vsebujejo 0,5 ml.
6 napolnjenih injekcijskih brizg z varnostno iglo, ki vsebujejo 0,5
ml.
6 napolnjenih injekcijskih brizg z varnost
                                
                                Read the complete document
                                
                            

Summary of Product characteristics

                                1
PRILOGA I
POVZETEK GLAVNIH ZNAČILNOSTI ZDRAVILA
2
1.
IME ZDRAVILA
_ _
Eporatio 1000 i.e./0,5 ml raztopina za injiciranje v napolnjeni
injekcijski brizgi
Eporatio 2000 i.e./0,5 ml raztopina za injiciranje v napolnjeni
injekcijski brizgi
Eporatio 3000 i.e./0,5 ml raztopina za injiciranje v napolnjeni
injekcijski brizgi
Eporatio 4000 i.e./0,5 ml raztopina za injiciranje v napolnjeni
injekcijski brizgi
Eporatio 5000 i.e./0,5 ml raztopina za injiciranje v napolnjeni
injekcijski brizgi
Eporatio 10.000 i.e./1 ml raztopina za injiciranje v napolnjeni
injekcijski brizgi
Eporatio 20.000 i.e./1 ml raztopina za injiciranje v napolnjeni
injekcijski brizgi
Eporatio 30.000 i.e./1 ml raztopina za injiciranje v napolnjeni
injekcijski brizgi
2.
KAKOVOSTNA IN KOLIČINSKA SESTAVA
Eporatio 1000 i.e./0,5 ml raztopina za injiciranje v napolnjeni
injekcijski brizgi
Ena napolnjena injekcijska brizga vsebuje 1000 mednarodnih enot (i.e.)
(8,3 µg) epoetina theta v
0,5 ml raztopine za injiciranje, kar ustreza 2000 i.e. (16,7 µg)
epoetina theta na ml.
Eporatio 2000 i.e./0,5 ml raztopina za injiciranje v napolnjeni
injekcijski brizgi
Ena napolnjena injekcijska brizga vsebuje 2000 mednarodnih enot (i.e.)
(16,7 µg) epoetina theta v
0,5 ml raztopine za injiciranje, kar ustreza 4000 i.e. (33,3 µg)
epoetina theta na ml.
Eporatio 3000 i.e./0,5 ml raztopina za injiciranje v napolnjeni
injekcijski brizgi
Ena napolnjena injekcijska brizga vsebuje 3000 mednarodnih enot (i.e.)
(25 µg) epoetina theta v
0,5 ml raztopine za injiciranje, kar ustreza 6000 i.e. (50 µg)
epoetina theta na ml.
Eporatio 4000 i.e./0,5 ml raztopina za injiciranje v napolnjeni
injekcijski brizgi
Ena napolnjena injekcijska brizga vsebuje 4000 mednarodnih enot (i.e.)
(33,3 µg) epoetina theta v
0,5 ml raztopine za injiciranje, kar ustreza 8000 i.e. (66,7 µg)
epoetina theta na ml.
Eporatio 5000 i.e./0,5 ml raztopina za injiciranje v napolnjeni
injekcijski brizgi
Ena napolnjena injekcijska brizga vsebuje 5000 mednarodnih enot (i.e.)
(41,7 µg) epoetina theta v
0,5 ml raztopine 
                                
                                Read the complete document
                                
                            

Documents in other languages

Patient Information leaflet Patient Information leaflet Bulgarian 27-09-2023
Summary of Product characteristics Summary of Product characteristics Bulgarian 27-09-2023
Public Assessment Report Public Assessment Report Bulgarian 16-12-2009
Patient Information leaflet Patient Information leaflet Spanish 27-09-2023
Public Assessment Report Public Assessment Report Spanish 16-12-2009
Patient Information leaflet Patient Information leaflet Czech 27-09-2023
Public Assessment Report Public Assessment Report Czech 16-12-2009
Patient Information leaflet Patient Information leaflet Danish 27-09-2023
Public Assessment Report Public Assessment Report Danish 16-12-2009
Patient Information leaflet Patient Information leaflet German 27-09-2023
Public Assessment Report Public Assessment Report German 16-12-2009
Patient Information leaflet Patient Information leaflet Estonian 27-09-2023
Public Assessment Report Public Assessment Report Estonian 16-12-2009
Patient Information leaflet Patient Information leaflet Greek 27-09-2023
Public Assessment Report Public Assessment Report Greek 16-12-2009
Patient Information leaflet Patient Information leaflet English 27-09-2023
Public Assessment Report Public Assessment Report English 16-12-2009
Patient Information leaflet Patient Information leaflet French 27-09-2023
Public Assessment Report Public Assessment Report French 16-12-2009
Patient Information leaflet Patient Information leaflet Italian 27-09-2023
Public Assessment Report Public Assessment Report Italian 16-12-2009
Patient Information leaflet Patient Information leaflet Latvian 27-09-2023
Public Assessment Report Public Assessment Report Latvian 16-12-2009
Patient Information leaflet Patient Information leaflet Lithuanian 27-09-2023
Summary of Product characteristics Summary of Product characteristics Lithuanian 27-09-2023
Public Assessment Report Public Assessment Report Lithuanian 16-12-2009
Patient Information leaflet Patient Information leaflet Hungarian 27-09-2023
Summary of Product characteristics Summary of Product characteristics Hungarian 27-09-2023
Public Assessment Report Public Assessment Report Hungarian 16-12-2009
Patient Information leaflet Patient Information leaflet Maltese 27-09-2023
Public Assessment Report Public Assessment Report Maltese 16-12-2009
Patient Information leaflet Patient Information leaflet Dutch 27-09-2023
Public Assessment Report Public Assessment Report Dutch 16-12-2009
Patient Information leaflet Patient Information leaflet Polish 27-09-2023
Public Assessment Report Public Assessment Report Polish 16-12-2009
Patient Information leaflet Patient Information leaflet Portuguese 27-09-2023
Summary of Product characteristics Summary of Product characteristics Portuguese 27-09-2023
Public Assessment Report Public Assessment Report Portuguese 16-12-2009
Patient Information leaflet Patient Information leaflet Romanian 27-09-2023
Public Assessment Report Public Assessment Report Romanian 16-12-2009
Patient Information leaflet Patient Information leaflet Slovak 27-09-2023
Public Assessment Report Public Assessment Report Slovak 16-12-2009
Patient Information leaflet Patient Information leaflet Finnish 27-09-2023
Public Assessment Report Public Assessment Report Finnish 16-12-2009
Patient Information leaflet Patient Information leaflet Swedish 27-09-2023
Public Assessment Report Public Assessment Report Swedish 16-12-2009
Patient Information leaflet Patient Information leaflet Norwegian 27-09-2023
Summary of Product characteristics Summary of Product characteristics Norwegian 27-09-2023
Patient Information leaflet Patient Information leaflet Icelandic 27-09-2023
Summary of Product characteristics Summary of Product characteristics Icelandic 27-09-2023
Patient Information leaflet Patient Information leaflet Croatian 27-09-2023

Search alerts related to this product

View documents history